Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Artelo Biosciences, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +2 vs. Q4 2025
- Shares held
- 46.5K
- −38.0K (−45.0%) vs. Q4 2025
- Total value
- $829.9K
- +$726.4K (+701.9%) vs. Q4 2025
- New holders
- 7
- 1 more added
- Sold out
- 5
- 0 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.4K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $992.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Altshuler Shaham Ltd | 889 | $484.2K | 0.01% | +889 | New |
| Kathmere Capital Management, LLC | 13,250 | $100.4K | 0.01% | +13,250 | New |
| Jane Street Group, LLC | 13,079 | $99.1K | 0.00% | +13,079 | New |
| Vanguard Capital Management LLC | 10,129 | $76.8K | 0.00% | +10,129 | New |
| Vanguard Fiduciary Trust Co | 3,139 | $23.8K | 0.00% | +3,139 | New |
| Citigroup Inc | 3,076 | $23.3K | 0.00% | +3,076 | New |
| Tower Research Capital LLC (TRC) | 2,826 | $21.4K | 0.00% | +923+48.5% | Added |
| Clear Street Group Inc. | 100 | $758 | 0.00% | +100 | New |
| Rothschild Investment LLC | 2 | $15 | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 1 | $8 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1 | $7 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 0 | $0 | 0.00% | −33,621−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −20,669−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −16,865−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −11,398−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |